Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dectrekumab (QAX576) in Eosinophilic Esophagitis
NCT01022970Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2009
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dectrekumab in eosinophilic esophagitis (EoE), sponsored by Novartis. Started Nov 2009; status: completed.
02
Drugs
dectrekumab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT01022970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01022970.